News

BerGenBio ASA – Updated key information related to the rights issue

BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue

BerGenBio ASA: Notice of Extraordinary General Meeting

BerGenBio ASA – Key information related to the rights issue

Announcement of fully underwritten rights issue

BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

BerGenBio ASA – Minutes from the annual general meeting 2025

BerGenBio ASA: Update on Strategic Review Process and Status of Activities

BerGenBio ASA: Notice of Annual General Meeting